Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aaron T. Gerds, Jingbo Yu, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn Scherber & Shreekant Parasuraman. (2023) Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs. Journal of Medical Economics 26:1, pages 843-849.
Read now
Read now
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo & Giuseppe Alberto Palumbo. (2023) The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors. Expert Opinion on Pharmacotherapy 24:13, pages 1449-1461.
Read now
Read now
T. Devos, P. Zachée, D. Bron, L. Noens, J. Van Droogenbroeck, P. Mineur, Y. Beguin, Z. Berneman, F. S. Benghiat, A. Kentos, C. Chatelain, H. Demuynck, J. Lemmens, K. Van Eygen, K. Theunissen, F. Trullemans, P. Pierre, W. Pluymers & L. Knoops. (2015) Myelofibrosis patients in Belgium: disease characteristics. Acta Clinica Belgica 70:2, pages 105-111.
Read now
Read now
Articles from other publishers (1)
John O. Mascarenhas & Srdan Verstovsek. (2022) The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128:14, pages 2717-2727.
Crossref
Crossref